NSE: DRREDDY · 30 September 2026 · Dated market coverage
- The stock is -1.51% at ₹1,233.00.
- Likely reason:Sectoral pressure and profit-taking after recent gains
- Approximate traded value is₹484.20 crore.
- It is -12.86% from its 52-week high and +11.99% from its 52-week low.
- The stock is being compared withNifty Pharmaalongside the Nifty 50.
Why Is Dr. Reddy S Laboratories Share Price Falling 1.51% Today?
Latest NSE EOD report: 2026-09-29. Today’s Volume: 3,926,974; 5-Day Avg. Volume: 3,088,680; 20-Day Avg. Volume: 1,814,132; Volume vs 20-Day Avg.: 2.16x; Delivery Quantity: 2,450,987; Delivery %: 45.84%; Number of Trades: 116,376.
Dr. Reddy’s Laboratories shares declined 1.51% to trade at ₹1,233.0, moving closer to the lower end of the day’s range between ₹1,215.2 and ₹1,244.6. Trading activity picked up notably, with volumes running at 2.16 times the 20-day average, signaling heightened participation as the stock pulled back.
The broader market and healthcare sector faced downward pressure during the session, with the Nifty falling 0.42% and the Nifty Pharma index dropping 1.84%. Dr. Reddy’s retracement aligns with the broader sectoral weakness, though the stock has managed a modest 1.80% gain over the past five trading sessions.
Company developments provide backdrop context without serving as direct catalysts for today’s price action. Notably, the exchange recently sought clarification regarding a media report concerning a voluntary license for Gilead’s HIV prevention drug, while the company also entered into an exclusive distribution agreement with Takeda Biopharmaceuticals India for Qdenga® in the private Indian market.
medium confidence
- Nifty Pharma sector fell 1.84%
- Volume was 2.16 times the 20-day average
- Prior two-session return stood at positive 4.24%
Ownership & Transaction Activity
WittyTrades Data Insight
Price Position:The stock is around the middle of the day’s trading range.
Move From Open:-0.56%.
Intraday Range:2.35% of the previous close.
5-Day Performance:+1.80%; 20-Day Performance:+6.61%.
Latest Company Developments
What Should Traders and Investors Watch Next?
- Upcoming financial results for the quarter ending September 30, 2026, scheduled for October 23, 2026
- Updates regarding the distribution rollout of Qdenga® in the Indian private market
- Delivery percentage trends relative to today’s elevated volume of 2.16x the 20-day average
Catalyst note:No single confirmed fundamental trigger drove today’s move, which appears driven by broader sectoral weakness and heightened volume activity.
Frequently Asked Questions
What is the likely reason for today’s move?
The stock’s decline mirrors broader weakness in the pharmaceutical sector and profit-taking following a multi-session rebound, accompanied by elevated trading volumes.
Is trading volume elevated?
Today’s volume is 3,926,974. The latest 20-day average available is 1,814,132, equivalent to about 2.16x of the recent average.
Before acting on this stock
Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review theWittyTrades subscription plans and research segments.
Article by:WittyTrades Research Desk